ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results https://finance.yahoo.com/news/clearpoint-neuro-reports-fourth-quarter-210700519.html ClearPoint Neuro GAAP EPS of -$0.69 misses by $0.01, revenue of $16.3M in-line https://seekingalpha.com/news/3808108-clearpoint-neuro-gaap-eps-of-0_69-misses-0_01-revenue-of-16_3m-in-line ClearPoint Neuro press release (NASDAQ:CLPT): FY GAAP EPS of -$0.69 misses by $0.01. Revenue of $16.3M (+27.0% Y/Y) in-line.

ClearPoint Neuro Reports Third Quarter 2021 Results https://www.globenewswire.com/news-release/2021/11/09/2330872/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2021-Results.html Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast ClearPoint Neuro EPS misses by $0.02, beats on revenue https://seekingalpha.com/news/3768099-clearpoint-neuro-eps-misses-0_02-beats-on-revenue ClearPoint Neuro (NASDAQ:CLPT): Q3 GAAP EPS of -$0.18 misses by $0.02. Revenue of $4.6M (+30.7% Y/Y) beats by $0.6M.

Ach Umsatz und EPS sind hier relativ zweitrangig. Da geht's eher um FDA Approvals, Pipeline etc.

Hab das Gefühl das es morgen runtergeht da die Schätzungen verfehlt wurden 🙈 Hoffentlich täusche ich mich 😅

https://www.stocktitan.net/news/CLPT/clear-point-neuro-reports-second-quarter-2021-g1p8jrp7djsn.html Record Case Volume Supported Clinically During the Quarter Second Quarter Highlights • Reported revenue of $3.4 million, a 38% year-over-year increase; • Clinical team supported a record 249 cases, a 98% year-over- year increase; • Increased biologics and drug delivery revenue to $1.4 million, a 19% year-over-year increase; • Added biologics and drug delivery relationships bringing current count of active partners to approximately 35 from approximately 30 in Q1 2021; and • Announced FDA clearance of the SmartFrame Array and performed first human cases. Business Outlook • The Company continues to estimate total case volume supported to be in the range of 900 – 1000 for 2021; and • The Company continues to estimate revenue to be between $16.0 and $17.5 million for 2021. ...

ClearPoint Neuro reports second quarter 2021 results - record case volume supported clinically during the quarter. #CLPT #earnings https://t.co/HAqlR2Owhz

ClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG https://www.globenewswire.com/news-release/2021/08/09/2277039/25687/en/ClearPoint-Neuro-Inc-Announces-Strategic-and-Commercial-Partnership-with-European-Surgical-Equipment-Leader-adeor-medical-AG.html

ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company https://seekingalpha.com/article/4446043-clearpoint-neuro-stock-path-to-being-the-neurological-navigation-platform Summary • ClearPoint Neuro is both a medical device and a biologics & drug delivery company. Both opportunities leverage a common navigation system with superior advantages over existing solutions. • New product developments in the pipeline allow them to penetrate into 90% of the operating room surgeries which they are not in today. • With a target to be in 100 centers conducting 100 cases each, 30 biologics & drug delivery partners, we believe the business to be worth at least $600M by 2025.

Danke 👍

We're proud to announce installation of our system at Hôpital Fondation Rothschild Paris advancing our strategy to set up more trial centers in the EU, UK & Middle East to support both our biologics & device partnerships. See more: https://t.co/ooEDMBOPT6 @FondARothschild #CLPT https://t.co/3ENpIhIWYa

Watch

Blackrock Neurotech, ClearPoint Neuro to Address Neurological Disorders With Novel Brain-Computer Interface Surgical Solution https://www.globenewswire.com/news-release/2021/07/21/2266822/25687/en/Blackrock-Neurotech-ClearPoint-Neuro-to-Address-Neurological-Disorders-With-Novel-Brain-Computer-Interface-Surgical-Solution.html